V. I. Kirpatovskiy

V. I. Kirpatovskiy

Auto-generated profile, based on publicly available information

V. I. Kirpatovskiy

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Experimental and Сlinical Urology
Verified
Journal Article
Closed access
NCN. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre
N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre
VKV.I. Kirpatovskiy
V.I. Kirpatovskiy
ASA.V. Sivkov
A.V. Sivkov
SGS.A. Golovanov
S.A. Golovanov
VDV.V. Drozhzheva
V.V. Drozhzheva
GEG.D. Efremov
G.D. Efremov
Острая почечная недостаточность (ОПН) является тяжелым жизненно-опасным осложнением. В урологической практике ОПН может развиваться после операции на единственной почке по поводу мочекаменной болезни,

29 June 2021 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
NFN. Lopatkin Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation
N. Lopatkin Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation
VKV.I. Kirpatovsky
V.I. Kirpatovsky
RMRussia Moscow
Russia Moscow
SGS.A. Golovanov
S.A. Golovanov
VDV.V. Drozhzheva
V.V. Drozhzheva
MVM.A Vekilyan
M.A Vekilyan
Introduction. The development of oxidative stress and nonspecific inflammation is one of the leading factors in the development of benign prostatic hyperplasia (BPH) and associated urination disorders in metabolic syndrome (MS). However, the specific mechanisms of these processes are not entirely clear. The purpose of the study. To study the activity of reactive oxygen species production and the functional state of mitochondria in the prostate and bladder and their role in the dysfunction of these organs using an experimental model of MS induction in rats. Material and methods. In 10 adult mongrel male rats MS was induced by keeping them on a high-calorie diet with an increased content of carbohydrates and fats for 3 months. 10 rats kept on a standard vivarium diet served as controls. The development of MS was confirmed by characteristic changes in the biochemical analysis of blood (hyperglycemia, hyperuricemia, dyslipidemia, hyperinsulinemia). In both series of rats, sections of the native prostate and bladder were examined by laser confocal microscopy and stained with fluorescent probes that characterize the activity of the production of reactive oxygen species (dichlorofluorescein-DCF) and the functional state of the mitochondria (tetramethylrodamine ether – TMRE). The activity of a number of intracellular enzymes (AST, ALT. Alkaline phosphatase, LDH) was investigated in the tissues and urine. Results. In rats with MS, the development of BPH and hypertrophy of the bladder were revealed, confirmed histologically. The study of sections of both organs by confocal microscopy revealed a significant increase in the production of reactive oxygen species by their cells and a decrease in the functional activity of mitochondria, which indicated the development of oxidant stress and tissue hypoxia. In the prostate, this was accompanied by a decrease in the secretory activity of the prostate glands, and in the bladder – the release of cytoplasmic enzymes from damaged cells into the urine, indicating cell damage. Conclusion. The causes of the development of a non-specific inflammatory process in the prostate and bladder, leading to dysfunction of these organs in MS, are increased production of reactive oxygen species and the development of tissue hypoxia.

6 August 2025 in Cancer Urology
Verified
Journal Article
Open access
PDF file
VKV. I. Kirpatovskiy
V. I. Kirpatovskiy
ASA. V. Sivkov
A. V. Sivkov
MNM. R. Nazirov
M. R. Nazirov
GEG. D. Efremov
G. D. Efremov
MSM. A. Sokolov
M. A. Sokolov
AKAndrei Kaprin
Andrei Kaprin
Background. One of the serious complications of chemotherapy with cisplatin is its nephrotoxic effect. Different variants of hydration therapy and thiol-containing drugs are used to prevent deterioration of renal function. However, if high doses of cisplatin are necessary, the effectiveness of therapy is limited, and the use of pharmacological agents is often accompanied by undesirable side effects, which forces the search for alternative ways of therapy.Aim. To study the effectiveness of prevention of nephrotoxic effect of cisplatin using a protein-peptide complex isolated from the pig embryonic brain (EPPC).Materials and methods. The study was conducted on 40 white mongrel male rats in 4 series. In the 1st series, rats were administered one intraperitoneal injection of cisplatin at a dose of 5 mg/kg. In the 2nd series, starting from the next day, an additional 10-day course of EPPC therapy was performed with daily intramuscular administration at a dose of 0.1 mL per rat. In the 3rd series, higher toxicity dose of cisplatin – 7 mg/kg – was used, and in the 4th series, EPPC therapy was used according to the same scheme as in the 2nd series. Severity of the toxic effect of cisplatin therapy was assessed by measuring biochemical parameters of blood and urine characterizing functional state of the kidneys on days 3, 7 and 14, and histological examination of the removed kidneys.Results. When cisplatin was administered at 5 mg/kg dose, all animals survived. In rats of the control series, concentration of creatinine and urea in the blood increased significantly with peak values on day 3, exceeding normal values by 146 % and 214 %, respectively. Glomerular filtration rate decreased by 75 %, and sodium and calcium reabsorption decreased by 72 % and 74 %, respectively. With EPPC therapy, the maximum increase in creatinine and urea concentrations was 100 % and 122 %, respectively, glomerular filtration rate decreased by only 48 %, and sodium and calcium reabsorption decreased by 60 % and 59 %, respectively. In experiments with a highly toxic dose of cisplatin in the control series, 80 % of rats died, and with EPPC therapy, the mortality rate was 50 %. The maximum increase in creatinine and urea concentrations in the control series was 1177 % and 1500 %, respectively, whereas with EPPC therapy it was 707 % and 1150 %, respectively. The decrease in glomerular filtration rate in the control series was 85 %, while with EPPC therapy it was 65 %. Sodium and calcium reabsorption in the control experiments decreased by 81 % for both cations, and in the experimental series by 57 % and 58 %, respectively. Histological examination in control experiments revealed marked glomerulosclerosis with necrotic and dystrophic changes in the renal tubules, and in experiments with 7 mg/kg dose of cisplatin massive interstitial hemorrhages were observed. Histological changes were significantly less pronounced during EPPC therapy.Conclusion. EPPC therapy significantly reduces the nephrotoxic effect of cisplatin, contributing to lower severity of impaired renal function and mortality when using the drug at high doses.

25 September 2023 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
VKV.I. Kirpatovskiy
V.I. Kirpatovskiy
NFN. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation
N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation
ASA.V. Sivkov
A.V. Sivkov
MSM.A. Sokolov
M.A. Sokolov
SGS.A. Golovanov
S.A. Golovanov
RMRussia Jsc «Pharm- Synthesis»; Moscow
Russia Jsc «Pharm- Synthesis»; Moscow
Introduction. In previously published experimental studies, we have shown that in rats with pre-modeled acute post-ischemic renal failure, therapy with a proteomic complex isolated from brain cells of

25 March 2023 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
RRR.A. Romanov
R.A. Romanov
RMRussia Moscow
Russia Moscow
AKA.V. Koryakin
A.V. Koryakin
ITI.S. Tolstov
I.S. Tolstov
VKV.I. Kirpatovskiy
V.I. Kirpatovskiy
BAB.YA. Alekseev
B.YA. Alekseev
Introduction. A significant improvement in the quality of prostate imaging by magnetic resonance (MRI), as well as the possibility of combining MRI and ultrasound images (fusion technology) for biopsy, open up new possibilities for the diagnosis of prostate cancer. The arsenal of methods of treating prostate cancer includes active surveillance and focal therapy for patients with low risk disease. That raises the question of improving the accuracy of diagnosis of tumor volume, stage and differentiation, which will largely determine the tactics of patient management. The aim of our work was to determine the diagnostic effectiveness of targeted MRI-assisted fusion biopsy of the prostate in comparison with standard biopsy. Materials and methods. We analyzed data of 356 patients who underwent tranperineal fusion biopsy. The age of the patients ranged from 48 to 72 years with an average value of 68.2 ± 2.1 years. The selection criteria for the study were an increase in the level of PSA (345 patients) – the range from 4 to 44.5 ng/ml (on average 6.02±0.21) or the detection of tumor-suspicious areas during finger rectal examination or transrectal ultrasound examination (TRUS) of the prostate gland (41 patients). Further methods of examination included multiparametric magnetic resonance imaging (MRI) and subsequent transperineal fusion biopsy in combination with standart biopsy. Results. In our study, the detection rate of prostate cancer was (82.6%) – the diagnosis was confirmed in 294 out of 356 examined patients. At the same time, with an increase in the PI-RADS gradation, the frequency of histological confirmation of cancer increased: 62.4% for PI-RADS 3 lesions, 89.6% for 4 and 96.7% for PI-RADS 5. Targeted biopsies confirmed the presence of prostate cancer in 246 cases out of 356 patients (69.1%). In relation to all cases of cancer detection, the proportion of positive targeted biopsies was 83.7%. Conclusion. Targeted MRI-assisted fusion biopsy allows detecting prostate cancer in 69.1%, but when supplemented with a polyfocal biopsy at standard points, the diagnostic accuracy increases to 82.6%. Thus, the data obtained allow us to conclude that based on the examination of patients with suspected prostate cancer using mpMRI with targeted fusion biopsy, supplemented by polyfocal biopsies at standard points, it is possible to determine the localization, extent and degree of malignancy of the tumor with a high degree of certainty.

25 September 2021 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
PRP.A. Hertzen Moscow scientific research oncology institute - branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia
P.A. Hertzen Moscow scientific research oncology institute - branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia
RRR.A. Romanov
R.A. Romanov
RMRussia Moscow
Russia Moscow
AKA.V. Koryakin
A.V. Koryakin
ASA.V. Sivkov
A.V. Sivkov
AKAndrei Kaprin
Andrei Kaprin
Introduction. Significant improvement in the quality of visualization of the prostate using magnetic resonance imaging (MRI), as well as the development of technologies for virtual combination of MRI and ultrasound images opens new horizons in the diagnosis of prostate cancer. The introduction of the PI-RADS system has allowed the standardization of MRI findings, and the development of fusion biopsy systems seeks to make diagnostics more accurate and less operator-dependent. Materials and methods. In this literature review, we evaluate the effectiveness of various biopsy approaches and discuss the prospects for targeted biopsies. The search for publications was carried out in the databases PubMed, e-library, Web of Scince et al. For citation, 55 literature sources were selected that met the search criteria for the keywords, «prostate cancer», «biopsy», «MRI», «TRUS», «fusion». Results. Diagnosis of prostate cancer using MRI. Modern technologies for radiological diagnosis of prostate cancer using magnetic resonance imaging (MRI) are based on the standardized PI-RADS protocol, using different modes (T2, diffusion-weighted images and contrast enhancement), which provides the best visualization of tumor-suspicious nodes in the prostate gland, allowing determination of lesion localization and size for subsequent targeted biopsy. Options for performing a prostate biopsy to diagnose prostate cancer. A description of the methods and effectiveness of transrectal and transperineal biopsy under ultrasound guidance is carried out - due to the fact that ultrasound diagnostics of prostate cancer has a rather low sensitivity due to small differences in the ultrasound structure of normal and tumor tissue of the prostate, an extended template biopsy technique was proposed, which involves puncture of the prostate through a special lattice. It also describes the technology of fusion biopsy and also provides literature data comparing the diagnostic accuracy of standard TRUS and fusion prostate biopsy, as well as the importance of transrectal / transperineal access. Questions for further study. Given the desire to reduce the number of biopsies while maintaining or even increasing the accuracy of diagnosing prostate cancer, data from studies investigating the feasibility of combining polyfocal (non-targeted) and targeted (targeted) biopsies are presented. Conclusion. The existing methods of non-targeted biopsy (polyfocal, saturation, template) and targeted (fusion biopsy) have their advantages and disadvantages, which currently do not allow making certain recommendations for their use, but a significant number of authors prefer MRI-as sisted, fusion -biopsy.